Skip to main content

Table 1 Baseline characteristics of study participants

From: Peri-event plasma PCSK9 and hsCRP after an acute myocardial infarction correlate with early deterioration of left ventricular ejection fraction: a cohort study

  Women Men Total
n= 24 (22.6%) 82 (77.4%) 106
Age 68 +/−  13 63 +/−  11.9 64.1 +/−  12.3
Time between onset of symptoms and sample (hours) 52.7 +/−  34.3 50.3 +/−  33.7 50.9 +/−  33.7
Body-mass index (Kg/m2) 25.5 +/−  5 27 +/−  4 26.7 +/−  4.3
Systolic blood pressure (mmHg) 127 +/−  24.4 133.8 +/−  25.2 132.2 +/−  25.1
Diastolic blood pressure (mmHg) 77.9 +/−  12.5 81 +/−  17.6 80.3 +/−  16.6
Heart rate (bpm) 82.4 +/−  18.1 75.6 +/−  20.5 77.1 +/−  20.1
Baseline troponin (ng/L) 3797.2 +/−  12,886 3397 +/−  10,609.3 3489.4 +/−  11,110.3
Glycated hemoglobin A1c (%) 7.0 +/−  1.7 6.6 +/−  1.3 6.7 +/−  1.4
Total cholesterol (mg/dL) 149.2 +/−  45.3 158.5 +/−  52.5 156.4 +/−  50.9
 mmol/L 3.84 +/−  1.17 4.10 +/−  1.36 4.05 +/−  1.32
HDL cholesterol (mg/dL) 30.7 +/− 17.8 27.3 +/−  9.6 28.1 +/−  11.9
 mmol/L 0.79 +/− 0.46 0.71 +/−  0.25 0.73 +/−  0.31
LDL cholesterol (mg/dL) 96.2 +/− 36.1 101.9 +/−  53.5 100.6 +/−  50.0
 mmol/L 2.49 +/−  0.93 2.64 +/−  1.39 2.61 +/−  1.30
Triglycerides (mg/dL) 111.5 +/−  47.0 146.8 +/−  99.1 138.8 +/−  91.0
 mmol/L 2.89 +/−  1.21 3.80 +/− 2.56 3.60 +/−  2.36
non-HDL cholesterol (mg/dL) 118.5 +/− 37.0 131.2 +/−  53.3 128.3 +/−  50.2
 mmol/L 3.07 +/−  0.96 3.40 +/− 1.38 3.32 +/− 1.30
hsCRP (mg/L) 22.5 +/−  29.6 26.4 +/−  24.2 25.5 +/−  25.5
Baseline plasma PCSK9 (ng/mL) 409.2 +/−  236.5 392.4 +/−  266.2 396.2 +/−  258.8
Baseline plasma NTproBNP (ng/mL) 162.5 +/− 100.4 315.2 +/−  603.9 280.6 +/−  536.3
Baseline plasma FABP3 (ng/mL) 6.3 +/− 8.6 22.3 +/−  61.4 18.6 +/−  54.5
Baseline LVEF (%) 54.0 +/−  10.7 57.4 +/−  8.5 56.6 +/− 9.1
Highest obstruction in coronary vessels (%) 59.0 +/− 40.9 79.1 +/−  31.2 74.8 +/− 34.3
Diabetes (%) 33.3% 25.6% 27.4%
Hypertension (%) 58.3% 54.9% 55.7%
Dyslipidemia (%) 45.8% 53.7% 51.9%
Prior myocardial infarction (%) 13.0% 20.7% 19.0%
History of cancer (%) 25.0% 11.0% 14.2%
Number of affected vessels (%)
 0 20.0% 5.3% 8.4%
 1 45.0% 20.0% 25.3%
 2 15.0% 36.0% 31.6%
 3 0.0% 22.7% 17.9%
 4 20.0% 13.3% 14.7%
 5 0.0% 2.7% 2.1%
Current use of statins (%) 41.7% 28.0% 31.1%
Current use of antihypertensives (%) 54.2% 47.6% 49.1%
Smoking (%) 4.2% 12.2% 10.4%
GRACE score 111 (27) 101 (23) 103 (25)
Mortality predicted by GRACE score 8.1 (7.2) 5.4 (4.0) 6.0 (5.0)
  1. Data are means +/− SD unless indicated otherwise. LVEF Left ventricular ejection fraction, hsCRP High-sensitivity C-reactive protein, PCSK9 Proprotein convertase subtilisin kexin type 9, NT-proBNP N-terminal prohormone of brain natriuretic peptide, FABP3 Heart-type fatty acid binding protein